Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.21)
# 473
Out of 4,996 analysts
227
Total ratings
64.56%
Success rate
9.59%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group | Maintains: Overweight | $325 → $395 | $344.08 | +14.80% | 20 | Sep 12, 2025 | |
| CNC Centene | Maintains: Equal-Weight | $33 → $28 | $34.86 | -19.68% | 13 | Aug 4, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $280.61 | +9.05% | 17 | Jul 25, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $71 → $60 | $74.40 | -19.35% | 10 | Apr 24, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $184 | $148.56 | +23.86% | 22 | Feb 5, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $5.42 | +84.50% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $4.04 | +36.14% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $18.42 | -59.28% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $17.53 | -31.55% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $188.99 | -23.28% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $191.98 | +90.12% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $760.55 | -44.78% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $6.20 | +1,835.48% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $254.95 | +143.18% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $318.61 | +56.93% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $75.77 | +63.65% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $286.17 | +11.12% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $153.71 | -54.46% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $179.56 | +8.60% | 6 | Oct 21, 2020 |
UnitedHealth Group
Sep 12, 2025
Maintains: Overweight
Price Target: $325 → $395
Current: $344.08
Upside: +14.80%
Centene
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $33 → $28
Current: $34.86
Upside: -19.68%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $280.61
Upside: +9.05%
Doximity
Apr 24, 2025
Maintains: Equal-Weight
Price Target: $71 → $60
Current: $74.40
Upside: -19.35%
Charles River Laboratories International
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $220 → $184
Current: $148.56
Upside: +23.86%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $5.42
Upside: +84.50%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $4.04
Upside: +36.14%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $18.42
Upside: -59.28%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $17.53
Upside: -31.55%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $188.99
Upside: -23.28%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $191.98
Upside: +90.12%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $760.55
Upside: -44.78%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $6.20
Upside: +1,835.48%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $254.95
Upside: +143.18%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $318.61
Upside: +56.93%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $75.77
Upside: +63.65%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $286.17
Upside: +11.12%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $153.71
Upside: -54.46%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $179.56
Upside: +8.60%